ANIK vs INGR
ANIK: Anika Therapeutics is a regenerative medicine company specializing in hyaluronic acid-based solutions for joint health and soft tissue repair. INGR: Ingredion is a leading global supplier of essential plant-based ingredients, including starches, sweeteners, and clean-label texturizers, that provide functionality and texture to a vast range of consumer and industrial products.
Side-by-side fundamentals
| Metric | ANIK | INGR | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $19.19 | $103.29 | |
| Market cap as of 2026-08-06 | $257M | $6.5B | |
| P/E as of 2026-08-06 | n/a | 9.82 | |
| PEG as of 2026-08-06 | n/a | 4.83 | |
| Net margin as of 2026-08-06 | -3.1% | +9.4% | INGR higher |
| Gross margin as of 2026-08-06 | +62.2% | +24.5% | ANIK higher |
| Operating margin as of 2026-08-06 | -4.2% | +13.1% | INGR higher |
| ROE as of 2026-08-06 | -2.7% | +15.8% | INGR higher |
| ROA as of 2026-08-06 | -2.0% | +8.6% | INGR higher |
| Debt / equity as of 2026-08-06 | 0.00 | 0.42 | ANIK lower |
| Revenue growth (YoY) as of 2026-08-06 | -2.5% | -2.2% | INGR higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | -3.1% | ANIK higher |
| Dividend yield as of 2026-08-06 | n/a | +3.1% | |
| Beta as of 2026-08-06 | 0.20 | 0.64 | |
| 1-year return as of 2026-08-05 close | +129.8% | -18.2% | ANIK higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.